Is Vycor Medical, Inc. overvalued or undervalued?

As of 1 October 2023, Vycor Medical, Inc. has moved from fair to attractive based on recent analyses. The company appears to be undervalued at this time. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.5, which suggest a strong financial position relative to its earnings and asset base.
In comparison to peers, Vycor Medical is favorably positioned against companies like Medtronic, which has a P/E ratio of 18.5, and Boston Scientific, with a P/B ratio of 3.1. This indicates that Vycor Medical is trading at a discount compared to its industry counterparts. Additionally, the stock has shown resilience, outperforming the Sensex in recent months, further supporting the notion of its undervaluation.